BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McCubrey JA, Yang LV, Abrams SL, Steelman LS, Follo MY, Cocco L, Ratti S, Martelli AM, Augello G, Cervello M. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. Cells 2022;11:2155. [PMID: 35883598 DOI: 10.3390/cells11142155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hossen MB, Islam MA, Reza MS, Kibria MK, Horaira MA, Tuly KF, Faruqe MO, Kabir F, Mollah MNH. Robust identification of common genomic biomarkers from multiple gene expression profiles for the prognosis, diagnosis, and therapies of pancreatic cancer. Comput Biol Med 2023;152:106411. [PMID: 36502691 DOI: 10.1016/j.compbiomed.2022.106411] [Reference Citation Analysis]
2 Zhang CY, Liu S, Yang M. Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options. World J Gastroenterol 2022; 28(48): 6827-6845 [DOI: 10.3748/wjg.v28.i48.6827] [Reference Citation Analysis]
3 Duan Y, Du Y, Mu Y, Gu Z, Wang C. Prognostic value, immune signature and molecular mechanisms of the SUMO family in pancreatic adenocarcinoma. Front Mol Biosci 2022;9:1096679. [PMID: 36589239 DOI: 10.3389/fmolb.2022.1096679] [Reference Citation Analysis]
4 Mccubrey JA, Abrams SL, Follo MY, Manzoli L, Ratti S, Martelli AM, Cervello M. Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies. Advances in Biological Regulation 2022. [DOI: 10.1016/j.jbior.2022.100917] [Reference Citation Analysis]